Director Tsuchimoto Kim R sold Monopar Therapeutics ($MNPR) shares once on the open market in the last 365 days, totaling about $356,000, with the most recent sale on July 14, 2025. These sales rank 7,190th among 11,678 insiders in our database, where the average is $8.6 million across about 6.4 transactions. Tsuchimoto has made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 2, 2025 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Director | A | Stock Options | 2924 | $0.00 | 2,924.0000 | 6,662,930 | 9999.99% | 0.04% |
| July 14, 2025 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Director | S | Common Stock | 8904 | $40.00 | 11,486.0000 | 6,102,560 | 43.67% | 0.15% |
| July 14, 2025 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Director | X | Stock Options | 4200 | $0.00 | 0.0000 | 6,102,560 | 100.00% | 0.07% |
| July 14, 2025 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Director | X | Stock Options | 4704 | $0.00 | 0.0000 | 6,102,560 | 100.00% | 0.08% |
| July 14, 2025 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Director | X | Common Stock | 8904 | $0.01 | 20,390.0000 | 6,102,560 | 77.52% | 0.15% |
| March 4, 2025 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Director | A | Stock Options | 11365 | $0.00 | 11,365.0000 | 6,102,560 | 9999.99% | 0.19% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 2998 | $0.73 | 57,429.0000 | 2,980,900 | 4.96% | 0.10% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 9957 | $0.00 | 74,412.0000 | 2,980,900 | 11.80% | 0.33% |
| June 30, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 9957 | $0.00 | 60,427.0000 | 2,980,900 | 19.73% | 0.33% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 4082 | $0.68 | 50,470.0000 | 2,980,900 | 7.48% | 0.14% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 9956 | $0.00 | 84,369.0000 | 2,980,900 | 10.56% | 0.33% |
| March 31, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 9956 | $0.00 | 54,552.0000 | 2,980,900 | 22.32% | 0.33% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 4073 | $0.34 | 43,870.0000 | 0 | 8.50% | 0.00% |
| Jan. 1, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 1231 | $0.00 | 45,101.0000 | 2,980,900 | 2.81% | 0.04% |
| Jan. 1, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 505 | $0.34 | 44,596.0000 | 2,980,900 | 1.12% | 0.02% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 9957 | $0.00 | 95,556.0000 | 0 | 9.44% | 0.00% |
| Jan. 1, 2024 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 1231 | $0.00 | 94,325.0000 | 2,980,900 | 1.29% | 0.04% |
| Dec. 31, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 9957 | $0.00 | 47,943.0000 | 0 | 26.21% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 3444 | $0.62 | 37,986.0000 | 0 | 8.31% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 9956 | $0.00 | 105,513.0000 | 0 | 8.62% | 0.00% |
| Sept. 30, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 9956 | $0.00 | 41,430.0000 | 0 | 31.63% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 5104 | $0.86 | 31,474.0000 | 0 | 13.95% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 14846 | $0.00 | 115,469.0000 | 0 | 11.39% | 0.00% |
| June 30, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 14846 | $0.00 | 36,578.0000 | 0 | 68.31% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 1842 | $1.39 | 21,732.0000 | 0 | 7.81% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 5067 | $0.00 | 130,315.0000 | 0 | 3.74% | 0.00% |
| March 31, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 5067 | $0.00 | 23,574.0000 | 0 | 27.38% | 0.00% |
| Feb. 1, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | A | Restricted Stock Units | 78234 | $0.00 | 135,382.0000 | 0 | 136.90% | 0.00% |
| Feb. 1, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | A | Stock Options | 102688 | $0.00 | 102,688.0000 | 0 | 9999.99% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 2067 | $2.37 | 17,779.0000 | 0 | 10.42% | 0.00% |
| Jan. 1, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 1230 | $0.00 | 19,009.0000 | 0 | 6.92% | 0.00% |
| Jan. 1, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | F | Common Stock | 502 | $2.37 | 18,507.0000 | 0 | 2.64% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 5067 | $0.00 | 55,917.0000 | 0 | 8.31% | 0.00% |
| Jan. 1, 2023 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Restricted Stock Units | 1230 | $0.00 | 1,231.0000 | 0 | 49.98% | 0.00% |
| Dec. 31, 2022 | Monopar Therapeutics | $MNPR | Tsuchimoto Kim R | Chief Financial Officer | M | Common Stock | 5067 | $0.00 | 19,846.0000 | 0 | 34.29% | 0.00% |